SCHEMBL30038447

SCHEMBL30038447

CCc1cc(=O)n2nc(C3=CCOCC3)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.61
▸ ACHE P22303 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ALDH1A1 P00352 8/20 0.37
▸ TSHR P16473 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ MAPT P10636 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ PIK3CD O00329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25036852 1.00 WRN (0.61) WRNACHEPOLBL3MBTL1ALDH1A1
SCHEMBL31295793 0.96 WRN (0.57) WRNACHEPOLBL3MBTL1ALDH1A1
SCHEMBL31295811 0.94 WRN (0.54) WRNACHEPOLBL3MBTL1ALDH1A1
SCHEMBL30984247 0.89 WRN (0.49) WRNPOLBL3MBTL1ALDH1A1TSHR
SCHEMBL31713883 0.89 WRN (0.49) WRNPOLBKDM4ECYP1A2CYP3A4
SCHEMBL31295764 0.88 WRN (0.49) WRNACHEPOLBL3MBTL1ALDH1A1
SCHEMBL30984191 0.88 WRN (0.49) WRNPOLBL3MBTL1MAPTPIK3CD
SCHEMBL31295794 0.88 WRN (0.49) WRNACHEPOLBL3MBTL1ALDH1A1
SCHEMBL31394684 0.86 WRN (0.67) WRNACHEPOLBL3MBTL1ALDH1A1
SCHEMBL25037213 0.86 WRN (0.69) WRNACHEPOLBL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360118-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-10-31 — — US disclosed
EP-4347596-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) Novartis AG (CH) 2024-04-10 — — EP disclosed
WO-2022249060-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) NOVARTIS AG (CH) 2022-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360118-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885ACHE 2983/4885POLB 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback